HSDT - Helius Medical Technologies, Inc.
| Previous Close | 2.9100 |
| Open | 2.8900 |
| Bid | 1.4000 x 2900 |
| Ask | 2.9900 x 800 |
| Day's Range | 2.7500 - 3.0800 |
| 52 Week Range | 1.7700 - 13.2000 |
| Volume | 368,543 |
| Avg. Volume | 187,688 |
| Market Cap | 75.436M |
| Beta (3Y Monthly) | -1.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2560 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- GlobeNewswire•2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Helius Medical Technologies, Inc. - HSDT
Pomerantz LLP is investigating claims on behalf of investors of Helius Medical Technologies, Inc. (“Helius” or the “Company”) (NASDAQ: HSDT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On April 10, 2019, Helius disclosed that the U.S. Food and Drug Administration (“FDA”) had declined the Company’s request for De Novo classification and clearance of its Portable Neuromodulation Stimulator device. The FDA stated that it lacked sufficient data to determine the relative contributions of the device and physical therapy in clinical studies. On this news, Helius’s stock price fell $44.11 per share, or 66.18%, to close at $2.10 per share on April 10, 2019, damaging investors.
- GlobeNewswire•2 days ago
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Helius Medical Technologies, Inc. Investors (HSDT)
LOS ANGELES, April 17, 2019 -- Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Helius Medical Technologies, Inc. (“Helius” or the “Company”).
- ACCESSWIRE•4 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Helius Medical Technologies, Inc. - HSDT
NEW YORK, NY / ACCESSWIRE / April 16, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Helius Medical Technologies, Inc. ("Helius" or the "Company") (NASDAQ: HSDT). ...
- GlobeNewswire•7 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Helius Medical Technologies, Inc. - HSDT
Pomerantz LLP is investigating claims on behalf of investors of Helius Medical Technologies, Inc. (“Helius” or the “Company”) (NASDAQ: HSDT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On April 10, 2019, Helius disclosed that the U.S. Food and Drug Administration (“FDA”) had declined the Company’s request for De Novo classification and clearance of its Portable Neuromodulation Stimulator device. The FDA stated that it lacked sufficient data to determine the relative contributions of the device and physical therapy in clinical studies. On this news, Helius’s stock price fell $44.11 per share, or 66.18%, to close at $2.10 per share on April 10, 2019, damaging investors.
- Business Wire•7 days ago
INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Helius Medical Technologies, Inc.
The law firm of Kirby McInerney LLP is investigating potential claims against Helius Medical Technologies, Inc. . This investigation concerns whether Helius has violated federal securities laws and/or engaged in other unlawful business practices.
- Business Wire•8 days ago
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Helius Medical Technologies, Inc. Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Helius Medical Technologies, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.
- Benzinga•9 days ago
The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 10) Fulgent Genetics Inc (NASDAQ: FLGT ) Intuitive Surgical, ...
- ACCESSWIRE•10 days ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Helius Medical Technologies, Inc. (HSDT)
NEW YORK, NY / ACCESSWIRE / April 10, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Helius Medical Technologies, Inc. ("Helius" or the ...
- GlobeNewswire•10 days ago
Helius Medical Technologies, Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
BOSTON, April 10, 2019 -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Helius Medical.
- MarketWatch•10 days ago
UPDATE: Helius Medical stock tanks after FDA declines request for approval of device used in brain injuries
Helius Medical Technologies Inc. shares slid 56% premarket Wednesday, after the company said the U.S. Food and Drug Administration has declined its request for De Novo classification and clearance of its Portable Neuromodulation Stimulator device (PoNS). The agency said it did not have enough data to determine the relative contributions of the device and physical therapy in clinical studies, but said the company could generate additional data and resubmit its application. The PoNS is a medical device used in Canada for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury when used with physical therapy. It remains an investigational device in the U.S. and European Union, where it is still under review. "We are understandably disappointed by the Agency's decision to decline our request for De Novo classification and 510(k) clearance, but Helius remains committed to generating the data to pursue a De Novo classification and 510(k) clearance of our PoNS device in the future for the treatment of patients with chronic balance deficit due to mmTBI, in order to bring our innovative therapy to more than 1.5 million Americans suffering from this condition," Helius Chief Executive Philippe Deschamps said in a statement. Helius stock has fallen 24% in the last 12 months, while the S&P 500 has gained 8.3%.
- GlobeNewswire•10 days ago
Helius Medical Technologies, Inc. Provides Update on FDA’s Review of its Request for De Novo Classification and 510(k) Clearance of the PoNS™ Device
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the U.S. Food and Drug Administration (the “FDA” or the “Agency”) has completed its review of the Company’s request for De Novo classification and 510(k) clearance of the Portable Neuromodulation Stimulator (PoNS™) device and has declined the Company’s request. In reaching its conclusion, the Agency noted that it did not have sufficient information to discern the relative independent contributions of the PoNS Device and physical therapy on the improvements from baseline in the effectiveness endpoints observed in the Company’s clinical studies.
- GlobeNewswire•18 days ago
Helius Medical Technologies to Release First Quarter of Fiscal Year 2019 Financial Results on May 9, 2019
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that first quarter of fiscal year 2019 financial results will be released after the market closes on Thursday, May 9, 2019. A live webcast of the call will also be provided on the Events section of the Company's investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. The webcast will be archived on the Events section of the Company’s investor relations website.
- ACCESSWIRE•last month
Uptick Newswire Hosts Helius Medical Technologies, Inc. on The Stock Day Podcast to Discuss Milestones in Their PoNS Technology
PHOENIX, AZ / ACCESSWIRE / March 20, 2019 / Uptick Newswire Stock Day Podcast welcomed Helius Medical Technologies, Inc. (HSDT) ("the Company"), a neurotech company focused on neurological wellness. President and CEO, Phil Deschamps, joined Stock Day host Everett Jolly. Jolly began the interview by asking Deschamps to share some background information about the Company.
- Simply Wall St.•last month
The Helius Medical Technologies (NASDAQ:HSDT) Share Price Has Gained 90% And Shareholders Are Hoping For More
While Helius Medical Technologies, Inc. (NASDAQ:HSDT) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 21% in the last quarter. ButRead More...
- Business Wire•last month
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Introduces Full Year 2019 Outlook
Helius Medical Technologies, Inc. , a neurotech company focused on neurological wellness, today reported financial results for the fourth quarter and full year ended December 31, 2018.
- GlobeNewswire•last month
Helius Medical Technologies, Inc. to Present at Oppenheimer’s 29th Annual Healthcare Conference
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in Oppenheimer’s 29th Annual Healthcare Conference at the Westin New York Grand Central in New York, New York. A live audio webcast of the conference presentation will be provided under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. The Portable Neuromodulation Stimulator (PoNS) is a licensed class II, noninvasive, medical device in Canada indicated for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury when used in conjunction with physical therapy. PoNS is an investigational medical device in the United States and the European Union (EU), it is currently under review for clearance by US FDA and by an EU Notified Body.
- GlobeNewswire•2 months ago
Helius Medical Technologies, Inc. Announces First Patients in Canada Treated with Commercially Available PoNS™ Treatment
Helius Medical Technologies, Inc (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it has begun treating patients in Canada with the Company’s Portable Neuromodulation Stimulator (PoNS™) Treatment. “We are excited to announce the treatment of the first patients in Canada with our PoNS™ device, signifying Helius’ transition to a commercial stage company,” said Philippe Deschamps, Helius’ Chief Executive Officer. “With approximately 400,000 individuals living with chronic balance issues due to a mild to moderate traumatic brain injury (“mTBI”), Canada represents an important market opportunity for Helius.
- GlobeNewswire•2 months ago
Helius Medical Technologies, Inc. Announces Company-Hosted Event at Medical Meeting in March
Helius will host a symposium titled “Achieving a New Balance: Neuromodulation with PoNS (Portable Neuromodulation Stimulator) for Chronic Balance Deficit Due to Mild to Moderate Traumatic Brain Injury” on Friday, March 15 from 12:15 – 1:15 p.m. EST. This symposium will provide details relevant to the current disease and treatment landscapes for patients with chronic balance and gait deficits associated with mild-to-moderate traumatic brain injury (mTBI). Program faculty will describe how noninvasive translingual neurostimulation of cranial nerves with the PoNS investigational medical device is a potentially novel treatment option for these patients.
- ACCESSWIRE•2 months ago
HELIUS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Helius Medical Technologies, Inc. To Contact The Firm
NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Helius Medical Technologies, Inc. ("Helius" ...
- PR Newswire•2 months ago
Lifshitz & Miller LLP Announces Investigation of Bristow Group Inc., Helius Medical Technologies, Inc., Nordstrom Inc., PriceSmart, Inc., Ryanair Holdings plc, Solid Biosciences Inc., and Vanda Pharmaceuticals Inc.
NEW YORK , Feb. 20, 2019 /PRNewswire/ -- Bristow Group Inc. (BRS) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the Company disclosing that it "did ...
- Business Wire•2 months ago
EQUITY ALERT: Rosen Law Firm Continues to Investigate Securities Claims Against Helius Medical Technologies, Inc.; Investors are Encouraged to Contact the Firm
Rosen Law Firm, a global investor rights law firm, is continuing to investigate potential securities claims on behalf of shareholders of Helius Medical Technologies, Inc. resulting from allegations that Helius may have issued materially misleading business information to the investing public.
